What is LevitasBio?
LevitasBio is a pioneering force in the life sciences sector, specializing in advanced sample preparation and characterization tools. At the core of its value proposition is a unique levitation technology that enables researchers to achieve superior cell enrichment and isolation. The company's product portfolio, which includes the LeviCell, LeviPrep, and LeviMetrics systems, addresses critical bottlenecks in single-cell genomics, cancer profiling, and 3D culture modeling.
By focusing on improving sample viability and throughput while simultaneously reducing operational costs, LevitasBio has established itself as an essential partner for academic institutions and high-throughput research facilities. The company's market position is defined by its ability to bridge the gap between complex biological sample handling and the high-precision requirements of modern diagnostic and therapeutic research.
How much funding has LevitasBio raised?
LevitasBio has raised a total of $61M across 3 funding rounds:
Series A
$8M
Series B
$18M
Series C
$35M
Series A (2017): $8M with participation from Decheng Capital
Series B (2021): $18M led by Decheng Capital and Thalys Medical
Series C (2022): $35M supported by Decheng Capital, Novalis LifeSciences, and Pavilion Capital
Key Investors in LevitasBio
Decheng Capital
A global investment firm specializing in early-stage life science and growth-stage healthcare companies, leveraging over $2.1 billion in capital to support revolutionary technologies.
Novalis LifeSciences
A boutique investment and advisory firm managing $500M in assets, focused on providing direct capital and strategic guidance to biopharma and life science tool developers.
Pavilion Capital
A growth-oriented private equity investor that provides strategic support and capital to fast-growing companies in the United States and Asia, focusing on high-growth technology sectors.
What's next for LevitasBio?
With the infusion of $35M, LevitasBio is poised to enter a new phase of operational scaling and product development. The strategic focus will likely center on expanding the commercial reach of the LeviCell platform and deepening its penetration into the biopharma and clinical research segments. As the company transitions from a development-heavy entity to a commercial-stage leader, the focus will shift toward optimizing supply chain efficiencies and broadening its intellectual property portfolio.
Furthermore, the backing from specialized life science investors suggests a roadmap that includes potential strategic partnerships and the acceleration of next-generation diagnostic tools. By leveraging its current capital position, LevitasBio is set to capitalize on the growing demand for automated, high-throughput biological analysis, ensuring it remains at the forefront of the precision medicine revolution.
